Can MiR-503 be used as a marker in diabetic patients with ischemic stroke?

Autor: Sheikhbahaei S; Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Manizheh D; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Mohammad S; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Hasan TM; Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Saman N; Mashhad University of Medical Sciences, Mashhad, Iran., Laleh R; Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Mahsa M; Isfahan University of Medical Sciences, Isfahan, Iran., Sanaz AK; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Shaghayegh HJ; Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. shaghayegh.haghjoo@gmail.com.
Jazyk: angličtina
Zdroj: BMC endocrine disorders [BMC Endocr Disord] 2019 Apr 29; Vol. 19 (1), pp. 42. Date of Electronic Publication: 2019 Apr 29.
DOI: 10.1186/s12902-019-0371-6
Abstrakt: Background: Some microRNAs are involved in diabetes pathology and some are known to have role in stroke. MiR-503 causes endothelial dysfunction in diabetic patients, predisposing to ischemia. There has been no study evaluating Mir-503 level in diabetic patients with or without ischemic stroke.
Methods: We designed a cross-sectional study to assess and compare serum level of MiR-503 in 4 groups of diabetic patients with ischemic stroke (I), non-diabetic patients with stroke (II), diabetic patients (III), and healthy controls (IV) in acute phase and 3 months later.
Results: Our data analysis showed that mean relative expression of MiR-503 in group (I) was significantly higher than 3 other groups (p < 0.05). The level of miR-503 was related to the patients' fasting blood glucose, Cholesterol level, NIHSS score and acute-phase modified Rankin Scale (mRS) (r = 0.49, p = 0.001, r = 0.5, p = 0.009, r = 0.45, p = 0.009, r = 0.48, p = 0.003, CI = 95%). Relative expression of miR in patients with mRS ≤ 2 (good outcome) was lower than in patients with mRS > 2 (poor outcome) (p = 0.008). After 3 months, level of miR decreased significantly only in group (I) (p = 0.002). Mean relative expression of miR-503 in chronic phase was not significantly different among groups (p-value> 0.05). There was no relation between miRNA level and mRS in chronic phase.
Conclusion: Hyperglycemia and ischemia together raise the level of MiR-503 acutely but it does not remain at high level after 3 months. Although higher miR was related to more disability in acute phase, it does not affect long-term outcome in ischemic patients. As MiR-503 is stable enough in blood it can be used as a potential diagnostic marker of an ischemic stroke in diabetic patient. Its level also is an indicator of stroke severity and patients' short-term outcome. It is recommended to study whether antagomiR-503 is a new therapeutic agent reducing the severity of and disability due to stroke.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje